Jeremy B Tuttle

US Patent:

56985495, Dec 16, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/474979

Inventors:

William D. Steers - Charlottesville VA
Jeremy B. Tuttle - Earlysville VA

Assignee:

UVA Patent Foundation - Charlottesville VA

International Classification:

A61K 3155
A61K 31135

US Classification:

514211

Abstract:

The instant invention discloses a method of treating hyperactive voiding associated with excessive nerve growth factor production and nerve growth in patients by administering a Ca. sup. ++ channel blocker. The Ca. sup. ++ channel blockers verapamil and diltiazem can be administered systemically to treat hyperactive voiding, such as is associated with benign prostatic hyperplasia and interstitial cystitis.

US Patent:

55039863, Apr 2, 1996

Filed:

May 12, 1994

Appl. No.:

8/241776

Inventors:

William D. Steers - Charlottesville VA
Jeremy B. Tuttle - Earlysville VA

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

G01N 3353
G01N 33543

US Classification:

435 792

Abstract:

The method of detecting lower urinary tract disease is disclosed through the comparison of the concentration of a neurotrophic factor present in a urine specimen in comparison with a predetermined normal concentration. Nerve growth factor, having a concentration of approximately less than 8 picograms per milliliter is the preferred factor. The concentration of nerve growth factor in the urine rises at the onset of the lower urinary tract disease and decreases as said disease progresses. Nerve growth factor production and nerve growth is inhibited by administering the Ca. sup. ++ channel blockers, verapamil or diltiazem.